Swedish Orphan Biovitrum AB Stock price

Equities

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm 07:59:32 2024-03-28 am EDT 5-day change 1st Jan Change
267.2 SEK -1.84% Intraday chart for Swedish Orphan Biovitrum AB -1.33% +0.07%
Sales 2023 22.12B 2.07B Sales 2024 * 23.95B 2.24B Capitalization 90.78B 8.48B
Net income 2023 2.41B 225M Net income 2024 * 3.6B 337M EV / Sales 2023 4.97 x
Net Debt 2023 19.26B 1.8B Net Debt 2024 * 14.77B 1.38B EV / Sales 2024 * 4.41 x
P/E ratio 2023
36.1 x
P/E ratio 2024 *
25.5 x
Employees 1,772
Yield 2023 *
-
Yield 2024 *
-
Free-Float 52.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.84%
1 week-1.33%
Current month+4.95%
1 month+5.45%
6 months+19.82%
Current year+0.07%
More quotes
1 week
262.60
Extreme 262.6
274.00
1 month
252.40
Extreme 252.4
283.80
Current year
243.20
Extreme 243.2
302.00
1 year
197.90
Extreme 197.9
302.00
3 years
127.10
Extreme 127.1
302.00
5 years
127.10
Extreme 127.1
302.00
10 years
65.25
Extreme 65.25
302.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 17-05-21
Director of Finance/CFO 57 18-07-19
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 20-12-31
Director/Board Member 59 12-04-25
Chairman 70 14-05-07
More insiders
Date Price Change Volume
24-03-28 267.2 -1.84% 197,348
24-03-27 272.2 +1.64% 328,104
24-03-26 267.8 -0.15% 540,104
24-03-25 268.2 -0.37% 311,572
24-03-22 269.2 -0.59% 387,948

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company's product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
267.2 SEK
Average target price
317.7 SEK
Spread / Average Target
+18.90%
Consensus
  1. Stock
  2. Equities
  3. Stock Swedish Orphan Biovitrum AB - Nasdaq Stockholm